Semaglutide Is the Most Banned Word on Facebook Ads
We have managed Facebook ad accounts for compounding pharmacies across 14 states. The single most banned word in our entire portfolio is "semaglutide." Facebook treats it as a prescription pharmaceutical, and any ad containing that word gets rejected within minutes, often before a human reviewer ever sees it.
The frustrating part is that semaglutide compounding is legal under FDA 503A. Pharmacies do it every day. But Facebook's automated policy enforcement does not distinguish between compounded preparations and branded pharmaceuticals. To Facebook's classifiers, semaglutide is semaglutide, and semaglutide requires a prescription, and prescription drugs cannot be advertised.
What Facebook's Policy Actually Says
Facebook's advertising policy on prescription drugs is buried in its "Prohibited Content" section under "Unacceptable Business Practices." The policy prohibits ads that promote the sale or use of prescription drugs, regardless of whether the advertiser holds a valid pharmacy license. The key phrase is "promote the sale." This is where every pharmacy gets it wrong.
Facebook interprets "promote the sale" broadly. If your ad mentions semaglutide and links to a page where someone can eventually obtain semaglutide, the system treats that as promotion. Even if you frame it as a consultation or an evaluation, the presence of the drug name in the ad creative triggers an automatic rejection.
The Three Triggers That Get Semaglutide Ads Banned
The drug name in ad copy. Semaglutide, Ozempic, Wegovy, Rybelsus. Any of these in your headline, primary text, or even image overlay text will trigger an instant rejection. The detection is keyword-based and does not consider context.
Before-and-after weight loss imagery. Facebook prohibits ads that depict negative self-perception or imply a body transformation. Semaglutide ads almost always feature weight loss messaging, which intersects with Facebook's personal attributes policy. Two policies hit the same ad.
Landing page content mirroring the ad. Even if your ad copy is clean, Facebook crawls your landing page. If the landing page contains semaglutide, Ozempic, or Wegovy prominently, the ad gets retroactively rejected. We have seen ads approved and live for 48 hours get pulled when the landing page crawl caught up.
FDA 503A, 503B, and DSHEA 1994
Facebook does not explicitly enforce FDA regulations, but its "compliance with applicable laws" clause means violating FDA rules can get your account banned. Here is the framework compounding pharmacies operate under:
FDA 503A permits licensed pharmacists to compound semaglutide for individual patients with a valid prescription. The compounding must be done in response to a specific prescription, not in advance for stock. Your advertising must reflect this: you are offering a pharmacy service, not a product.
FDA 503B applies to outsourcing facilities that compound larger batches without patient-specific prescriptions. If you hold a 503B registration, your ads must include disclaimers about the scope of your compounding, and you cannot imply FDA approval of your compounded products, because compounded drugs are not FDA-approved.
DSHEA 1994 does not cover semaglutide because semaglutide is a prescription drug, not a dietary supplement. But Facebook reviewers frequently confuse the two categories. If your pharmacy also compounds peptide supplements that fall under DSHEA, keep those campaigns completely separate. Cross-contamination between supplement and pharmaceutical campaigns confuses reviewers and gets both banned.
How We Got Semaglutide Ads Running Again
Strip the drug name from everything. Replace "semaglutide" with "GLP-1 therapy" or "compounded weight management." The ad, the landing page headline, the meta description, the image alt text. Every surface. This is not about hiding what you do. It is about not triggering the keyword filter before a human can review the context.
Center the consultation, not the compound. Your ad should be about accessing a medical consultation for weight management. The compound is what the patient receives after the consultation, not what you are advertising. This distinction is critical: you are advertising a healthcare service, not a drug.
Build a fully disclaimered landing page. Every landing page must include: the FDA 503A or 503B framework you operate under, a clear statement that compounded medications require a prescription, no dosing or efficacy claims, and a visible consultation flow that gates access to any treatment. The page structure must tell the reviewer: this is a medical practice, not a pill shop.
Complete BAV before launching. Facebook's Business Asset Verification is mandatory for health-related advertisers. Submit your pharmacy license, DEA registration, state board of pharmacy certificate, and business incorporation documents. BAV approval typically takes 5 to 7 business days. Do not launch ads before verification is confirmed, or you will waste ad spend on ads that get retroactively banned.
Semaglutide Campaign Restored in 6 Days
A Florida compounding pharmacy had four semaglutide ads rejected and their ad account restricted. They came to us after a week of submitting appeals that went nowhere. The problem was immediately obvious: every ad contained the word "semaglutide" in the headline and their landing page linked to a product page with a pricing table.
We rewrote their ads to promote "GLP-1 weight management consultations" and rebuilt their landing page as a medical intake form with FDA 503A disclaimers and no mention of semaglutide anywhere on the page. We also completed their BAV submission with pharmacy board documentation they had not previously uploaded.
Within six days of resubmission, all four ads were approved and the account restriction was lifted. The pharmacy has been running those ads for seven months with zero additional rejections. Their cost per consultation dropped 40 percent because they were no longer losing ad spend to rejected campaigns.
Continue Reading
For the Meta-specific compliance overview, see peptide ads rejected on Meta. If you are running tirzepatide ads, tirzepatide reversal strategies covers the GLP-1/GIP specific approach.
Ready to run these ads? Book a call → calendly.com/custodio-2/30min